[go: up one dir, main page]

LT3320912T - Indolamino 2,3-dioksigenaze grindžiama imunoterapija - Google Patents

Indolamino 2,3-dioksigenaze grindžiama imunoterapija

Info

Publication number
LT3320912T
LT3320912T LTEP17194619.7T LT17194619T LT3320912T LT 3320912 T LT3320912 T LT 3320912T LT 17194619 T LT17194619 T LT 17194619T LT 3320912 T LT3320912 T LT 3320912T
Authority
LT
Lithuania
Prior art keywords
dioxigenase
indolamine
based immunotherapy
immunotherapy
Prior art date
Application number
LTEP17194619.7T
Other languages
English (en)
Inventor
Mads Hald Andersen
Per Thor Straten
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of LT3320912T publication Critical patent/LT3320912T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTEP17194619.7T 2008-04-17 2009-04-17 Indolamino 2,3-dioksigenaze grindžiama imunoterapija LT3320912T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17
PCT/DK2009/000095 WO2009143843A1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy
EP09753556.1A EP2280721B1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy

Publications (1)

Publication Number Publication Date
LT3320912T true LT3320912T (lt) 2021-07-12

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP09753556.1T LT2280721T (lt) 2008-04-17 2009-04-17 Indolamino 2,3-dioksigenazės pagrindo imunoterapija
LTEP17194619.7T LT3320912T (lt) 2008-04-17 2009-04-17 Indolamino 2,3-dioksigenaze grindžiama imunoterapija

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP09753556.1T LT2280721T (lt) 2008-04-17 2009-04-17 Indolamino 2,3-dioksigenazės pagrindo imunoterapija

Country Status (20)

Country Link
US (6) US9433666B2 (lt)
EP (3) EP3320912B1 (lt)
JP (2) JP2011520783A (lt)
CN (2) CN102088994B (lt)
AU (1) AU2009253539B2 (lt)
CA (1) CA2721150C (lt)
CY (2) CY1120352T1 (lt)
DK (2) DK2280721T3 (lt)
ES (2) ES2870596T3 (lt)
HR (2) HRP20180282T1 (lt)
HU (2) HUE037973T2 (lt)
IL (1) IL208781A (lt)
LT (2) LT2280721T (lt)
NO (1) NO2280721T3 (lt)
NZ (1) NZ588757A (lt)
PL (2) PL2280721T3 (lt)
PT (2) PT3320912T (lt)
SI (2) SI3320912T1 (lt)
WO (1) WO2009143843A1 (lt)
ZA (1) ZA201008056B (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2280721T (lt) 2008-04-17 2018-02-12 Io Biotech Aps Indolamino 2,3-dioksigenazės pagrindo imunoterapija
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
JP6605591B2 (ja) * 2014-05-29 2019-11-13 スプリング バイオサイエンス コーポレーション 抗インドールアミン２，３−ジオキシゲナーゼ１抗体及びその診断的使用
EP3193917B9 (en) * 2014-09-17 2022-02-16 IO Biotech ApS Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
DK3313431T5 (da) 2015-06-29 2024-10-07 Ose Immunotherapeutics Fremgangsmåde til inducering af et tidligt t-hukommelsesrespons med antitumorvaccine med korte peptider
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
HRP20240052T1 (hr) * 2016-03-04 2024-03-29 Io Biotech Aps Kombinirana terapija protiv raka
US20190328857A1 (en) 2016-06-10 2019-10-31 Io Biotech Aps Calr and jak2 vaccine compositions
WO2018067660A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
ES2863926T3 (es) * 2016-10-14 2021-10-13 Univ Zuerich Ensayo de indolamina-2,3-dioxigenasa para el diagnóstico y pronóstico de cáncer de próstata
RU2769474C2 (ru) * 2017-01-20 2022-04-01 Атара Байотерапьютикс, Инк. Способы лечения рассеянного склероза с использованием аутологичных т-клеток
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP4035675A3 (en) 2017-01-27 2022-11-16 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
KR102624844B1 (ko) 2017-11-27 2024-01-12 오제 이뮈노테라프틱스 암의 향상된 치료
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
CN114981413A (zh) * 2019-10-23 2022-08-30 昆士兰医学研究所理事会 过继免疫治疗
EP4176053A4 (en) * 2020-07-02 2024-12-25 The Regents of the University of California PERSISTENT MEMORY T CELL RESPONSES TO CANCER AND INFECTIOUS DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID CATABOLIC PATHWAYS
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
WO2024178160A2 (en) * 2023-02-21 2024-08-29 Salvitus, Inc. Recombinant phage, probiotic vaccines and therapeutics, related compositions and methods of use
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1997000966A1 (en) * 1995-06-20 1997-01-09 Merck & Co., Inc. Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1221349A (zh) 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1185687A1 (en) 1999-05-03 2002-03-13 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
WO2002059377A2 (en) 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US7763251B2 (en) 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060205934A1 (en) 2002-12-05 2006-09-14 Macina Roberto A Compositions, splice variants and methods relating to breast specific genes and proteins
AU2003287131B2 (en) 2002-12-13 2008-07-24 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US20050186289A1 (en) 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
WO2006005185A1 (en) * 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (ido) inhibitors
WO2006056304A2 (en) 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
JP2008528643A (ja) 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
ES2401482T3 (es) 2005-05-10 2013-04-22 Incyte Corporation Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
MX342474B (es) * 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
EP2023715B1 (en) * 2006-05-18 2014-01-08 Lankenau Institute for Medical Research Indoleamine-2, 3-dioxygenase-2
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
LT2280721T (lt) 2008-04-17 2018-02-12 Io Biotech Aps Indolamino 2,3-dioksigenazės pagrindo imunoterapija

Also Published As

Publication number Publication date
DK3320912T3 (da) 2021-05-31
US12233103B2 (en) 2025-02-25
IL208781A (en) 2017-09-28
US20220202922A1 (en) 2022-06-30
NZ588757A (en) 2012-05-25
PL3320912T3 (pl) 2021-10-25
HUE055338T2 (hu) 2021-11-29
PL2280721T3 (pl) 2018-04-30
EP3320912A1 (en) 2018-05-16
PT2280721T (pt) 2018-02-16
US20220249641A1 (en) 2022-08-11
US20110318372A1 (en) 2011-12-29
US11324813B2 (en) 2022-05-10
CN102088994A (zh) 2011-06-08
WO2009143843A1 (en) 2009-12-03
CA2721150A1 (en) 2009-12-03
JP6016966B2 (ja) 2016-10-26
US20190201512A1 (en) 2019-07-04
CN102088994B (zh) 2014-06-25
ES2657963T3 (es) 2018-03-07
CY1124279T1 (el) 2022-07-22
US20170049868A1 (en) 2017-02-23
PT3320912T (pt) 2021-05-24
CN104056261A (zh) 2014-09-24
NO2280721T3 (lt) 2018-04-14
EP2280721A1 (en) 2011-02-09
CA2721150C (en) 2017-09-26
JP2011520783A (ja) 2011-07-21
SI2280721T1 (en) 2018-02-28
US9433666B2 (en) 2016-09-06
ZA201008056B (en) 2011-07-27
EP2280721B1 (en) 2017-11-15
AU2009253539A1 (en) 2009-12-03
AU2009253539B2 (en) 2014-03-20
EP3320912B1 (en) 2021-03-31
JP2015129182A (ja) 2015-07-16
ES2870596T3 (es) 2021-10-27
US20230233657A1 (en) 2023-07-27
HUE037973T2 (hu) 2018-09-28
DK2280721T3 (da) 2018-01-29
HRP20210766T1 (hr) 2021-07-23
US11648302B2 (en) 2023-05-16
CY1120352T1 (el) 2019-07-10
HRP20180282T1 (hr) 2018-03-23
US10258678B2 (en) 2019-04-16
CN104056261B (zh) 2017-01-11
LT2280721T (lt) 2018-02-12
EP3915570A1 (en) 2021-12-01
SI3320912T1 (sl) 2021-08-31
IL208781A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
LT3320912T (lt) Indolamino 2,3-dioksigenaze grindžiama imunoterapija
NO2021006I1 (no) Quofenix, delafloksacin
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ME03065B (me) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DK3056214T3 (da) Hidtil ukendte adjuvanssammensætninger
EP2520575A4 (en) 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
DK2344471T3 (da) 7-piperidinalkyl-3,4-dihydroquinolon-derivat
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
BRPI0922391A2 (pt) pneumático.
UY33125A (es) Diaza-espiro-[5,5]-undecanos
BRPI0907925A2 (pt) Ativadores de glicoquinase.
BRPI0914533A2 (pt) "métodos"
BRPI0923418A2 (pt) pneumático.
BRPI0909422A2 (pt) conjunto de artigos.
BRPI0912716A2 (pt) composto.
BRPI0923387A2 (pt) pneumático.
FR2932490B1 (fr) Composition polyamide.
FR2933822B1 (fr) Alternateur.
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
BRPI0922477A2 (pt) transportador.
FR2932857B1 (fr) Agrafe.